NCT05952557 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05952557
Title	An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)
Acronym	CAMBRIA-2
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	Her2-receptor negative breast cancer
Therapies	Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Exemestane Abemaciclib + Camizestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole Exemestane Anastrozole Letrozole
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| ROU \| POL \| NZL \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| EST \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG

No variant requirements are available.